» Articles » PMID: 36502691

Robust Identification of Common Genomic Biomarkers from Multiple Gene Expression Profiles for the Prognosis, Diagnosis, and Therapies of Pancreatic Cancer

Overview
Journal Comput Biol Med
Publisher Elsevier
Date 2022 Dec 12
PMID 36502691
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer (PC) is one of the leading causes of cancer-related death globally. So, identification of potential molecular signatures is required for diagnosis, prognosis, and therapies of PC. In this study, we detected 71 common differentially expressed genes (cDEGs) between PC and control samples from four microarray gene-expression datasets (GSE15471, GSE16515, GSE71989, and GSE22780) by using robust statistical and machine learning approaches, since microarray gene-expression datasets are often contaminated by outliers due to several steps involved in the data generating processes. Then we detected 8 cDEGs (ADAM10, COL1A2, FN1, P4HB, ITGB1, ITGB5, ANXA2, and MYOF) as the PC-causing key genes (KGs) by the protein-protein interaction (PPI) network analysis. We validated the expression patterns of KGs between case and control samples by box plot analysis with the TCGA and GTEx databases. The proposed KGs showed high prognostic power with the random forest (RF) based prediction model and Kaplan-Meier-based survival probability curve. The KGs regulatory network analysis detected few transcriptional and post-transcriptional regulators for KGs. The cDEGs-set enrichment analysis revealed some crucial PC-causing molecular functions, biological processes, cellular components, and pathways that are associated with KGs. Finally, we suggested KGs-guided five repurposable drug molecules (Linsitinib, CX5461, Irinotecan, Timosaponin AIII, and Olaparib) and a new molecule (NVP-BHG712) against PC by molecular docking. The stability of the top three protein-ligand complexes was confirmed by molecular dynamic (MD) simulation studies. The cross-validation and some literature reviews also supported our findings. Therefore, the finding of this study might be useful resources to the researchers and medical doctors for diagnosis, prognosis and therapies of PC by the wet-lab validation.

Citing Articles

Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts.

Feng H, Chen Z, Li J, Feng J, Yang F, Meng F iScience. 2025; 28(3):111693.

PMID: 40060891 PMC: 11889678. DOI: 10.1016/j.isci.2024.111693.


Screening of common genomic biomarkers to explore common drugs for the treatment of pancreatic and kidney cancers with type-2 diabetes through bioinformatics analysis.

Ajadee A, Mahmud S, Sarkar A, Noor T, Ahmmed R, Haque Mollah M Sci Rep. 2025; 15(1):7363.

PMID: 40025145 PMC: 11873208. DOI: 10.1038/s41598-025-91875-3.


The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO.

Heidari R, Assadollahi V, Marashi S, Elahian F, Mirzaei S Cancer Rep (Hoboken). 2025; 8(1):e70098.

PMID: 39764737 PMC: 11705453. DOI: 10.1002/cnr2.70098.


Exploring bacterial key genes and therapeutic agents for breast cancer among the Ghanaian female population: Insights from In Silico analyses.

Kibria M, Ali M, Haque Mollah M PLoS One. 2024; 19(11):e0312493.

PMID: 39585882 PMC: 11588272. DOI: 10.1371/journal.pone.0312493.


Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches.

Sarker A, Aziz M, Hossen M, Mollah M, Al-Amin , Haque Mollah M Sci Rep. 2024; 14(1):27545.

PMID: 39528802 PMC: 11554889. DOI: 10.1038/s41598-024-79391-2.